IFNG and breast cancer: In agreement with previous studies26,27, here we show that PD-L1 is overexpressed in cancer cells as a result of treatment with a variety of anti-cancer agents; exposure of BC cell lines to various small-molecule therapeutics resulted in a general phenomenon of PD-L1 upregulation, through a non-canonical signaling pathway that does not involve IFN-γ.